Achieve Life Sciences (ACHV) Invested Capital (2010 - 2026)

Achieve Life Sciences has disclosed Invested Capital across 17 years of filings, most recently posting $10.7 million for Q1 2026.

• Quarterly Invested Capital fell 6.93% year-over-year to $10.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.7 million (down 6.93% YoY) and the FY2025 annual result came in at $25.2 million, up 20.69% from the prior year.
• Invested Capital slipped to $10.7 million in Q1 2026, from $25.2 million in the prior quarter.
• Over five years, Invested Capital peaked at $66.6 million in Q1 2024 and troughed at -$920000.0 in Q4 2023.
• A 5-year average of $22.6 million and a median of $20.9 million in 2024 frame the typical range for Invested Capital.
• Annual changes were most pronounced in 2023 — Invested Capital tumbled 103.77% — and 2024, when it jumped 2371.63%.
• Tracing ACHV's Invested Capital over 5 years: stood at $24.4 million in 2022, then slumped by 103.77% to -$920000.0 in 2023, then soared by 2371.63% to $20.9 million in 2024, then advanced by 20.69% to $25.2 million in 2025, then slumped by 57.66% to $10.7 million in 2026.
• Business Quant data shows ACHV's Invested Capital at $10.7 million in Q1 2026, $25.2 million in Q4 2025, and $34.8 million in Q3 2025.